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Abstract
Purpose Vascular closure devices are routinely used after
many vascular interventional radiology procedures. How-
ever, there have been no major multicenter studies to assess
the safety and effectiveness of the routine use of closure
devices in interventional radiology.
Methods The CIRSE registry of closure devices with an
anchor and a plug started in January 2009 and ended in
August 2009. A total of 1,107 patients were included in the
registry.
Results Deployment success was 97.2%. Deployment
failure speciﬁed to access type was 8.8% [95% conﬁdence
interval (95% CI) 5.0–14.5] for antegrade access and 1.8%
(95% CI 1.1–2.9) for retrograde access (P = 0.001). There
was no difference in deployment failure related to local
PVD at the access site. Calciﬁcation was a reason for
deployment failure in only \0.5% of patients. Postde-
ployment bleeding occurred in 6.4%, and most these
(51.5%) could be managed with light manual compression.
During follow-up, other device-related complications were
reported in 1.3%: seven false aneurysms, three hematoma
[5.9 cm, and two vessel occlusions.
Conclusion The conclusion of this registry of closure
devices with an anchor and a plug is that the use of this
device in interventional radiology procedures is safe, with a
low incidence of serious access site complications. There
seems to be no difference in complications between ante-
grade and retrograde access and other parameters.
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Introduction
Currently, vascular closure devices are routinely used after
many vascular interventional radiology procedures. In
cardiology, many large studies on safety and effectiveness
have been published, where reduction in procedure time
and early ambulation and discharge were the main end-
points. However, there have been no major multicenter
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use of closure devices in interventional radiology. Only
single-center data have been published [1–4]. This lack of
data, combined with the popularity of closure device
complications at morbidity and mortality conferences and
in case reports, might give a biased impression about
closure devices [5, 6]. If their safety is to be accurately
assessed, it is necessary to ascertain the number of all
closure devices used in a given institute in relation to the
rate of complications. To obtain these data, CIRSE con-
ducted a registry to investigate the safety of closure devi-
ces. Although the initial registry was intended to be open to
all CE-marked closure devices, only closure devices with
an anchor and plug were ﬁnally included.
Registry Design
The registry was advertised through CIRSE e-mail and on
the CIRSE Web site. It was open to all centers with more
than 50 closure devices experience. The registry was
conducted online and was hosted on an external server. The
design of the registry, data management, and ﬁnal reporting
were performed by CIRSE. Device companies were not
involved in this process. The registry was designed to
collect data from up to 100 sites by members of CIRSE and
intended to recruit 1,000 patients. Collected data included
deployment success, time to hemostasis, time to mobili-
zation, and time to discharge. A record of all in-hospital
access site complications was also made. Patients returning
with late closure device problems could also be included in
this registry.
Material and Methods
The registry started in January 2009 and ended in August
2009. Twenty-eight centers from 10 European countries
participated in the registry. Only acute procedure-related
data were entered, and no direct patient identiﬁable infor-
mation was obtained; there were no privacy issues. The
medical ethical commission in one larger center looked at
the protocol and concluded that no informed consent was
needed. Only devices with an anchor and extravascular
plug (Angio-Seal, St. Jude Medical) were included in the
registry. A minimum experience of 50 closure devices was
required to enter patients onto the registry. The contributors
to the registry were asked to include consecutive patients.
No in-or exclusion criteria on the indication for closure
device use were given. Complications were registered
before discharge and in follow-up; only complications
in patients who returned spontaneously with a puncture
site–related problem were registered. These were not
linked to the original procedure for privacy reasons.
All v
2 tests we performed for statistical analysis used
were standard tests.
Results
A total of 1,107 patients were included in the registry. The
number of included patients per country varied between
438 and 16. Lowest inclusion per center was 1 and highest
inclusion per center was 172. Of the included patients, 676
were male. Mean age distribution was between 55 and
75 years, with no difference between male and female
patients. A total of 80.4% of all patients were on some form
of antithrombotic medication. A total of 44.3% were
receiving aspirin, 57.7% unfractionated heparin, and 10.7%
clopidogrel. A total of 84.7% of all procedures were per-
formed with retrograde arterial access and 15.3% with
antegrade access. A total of 34.4% [95% conﬁdence
interval (95% CI) 27.2–42.2] of all patients with antegrade
access had diabetes. For retrograde punctures, this was
22.5% (95% CI 19.8–25.4). This difference was highly
signiﬁcant, with a P-value of 0.002. There was no differ-
ence in type of access between male and female patients.
The percentage of obese patients (body mass index of[25)
was equal in antegrade and retrograde access, with 23.9
and 25.1%, respectively.
Deployment success was 97.2%. Failures were due to
calciﬁcations (n = 5), device problems (n = 7), and other
unspeciﬁed (n = 16). Deployment failure speciﬁed to
access type was 8.8% (95% CI 5.0–14.5) for antegrade
access and 1.8% (95% CI 1.1–2.9) for retrograde access
(P = 0.001). There was no difference in deployment fail-
ure related to sheath size or French size of the closure
device (6F or 8F). Nor was deployment success related to
local PVD at the access site. Calciﬁcation was a reason for
deployment failure in only\0.5% of patients.
Postdeployment bleeding occurred in 6.4%, and most of
these (51.5%) could be managed with light manual com-
pression. Pressure dressing was only applied in 22.1%. In
71.6% of the pressure dressing population, the pressure was
applied for\1h .
There were 26 reported complications, of which 13
(1.2%) were reported as serious: two false aneurysms, six
hematoma [5.9 cm, 1 signiﬁcant bleeding, two vessel
occlusion, and two vessel dissections. Access site compli-
cations were generally equal for antegrade and retrograde
access, at 4% (95% CI 1.6–8.8) and 2.3% (95% CI
1.4–3.6), respectively. This difference was not signiﬁcant
(P = 0.342).
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patients. A total of 43.7% of all patients were discharged
between 9 and 24 h after the procedure, and 52.3% were
discharged after more than 24 h. The closure device only
shortened the anticipated discharge time in 12.2% of
patients. Discharge was delayed after closure device in
0.9%.
During follow-up, other device-related complications
were reported in 1.3% (n = 15): seven false aneurysms,
three hematoma[5.9 cm, two vessel occlusions, one par-
tial occlusion of the vessel, and two severe pain at the
access site.
We have looked at the data concerning complications
and could not ﬁnd a difference between high and low
inclusion centers. However, the number of complications is
too small to draw any scientiﬁc conclusions.
Discussion
The current negative view of the use of closure devices in
peripheral vascular disease has been heavily inﬂuenced by
the anecdotal reporting of complications. These compli-
cations should be viewed in the context of the overall usage
of these devices in interventional practice to get a true
incidence of these complications. To get a better under-
standing of the safety and the possible advantages of rou-
tine use of these devices after an interventional radiology
procedure, CIRSE embarked on an independent closure
device registry, which included more than 1,100 patients
over a period of 7 months, demonstrating that these devices
are widely used in interventional radiology. Most devices
(84.7%) are still used after retrograde access, probably
including many over the bifurcation procedures. Almost all
patients in this registry ([80%) were receiving some form
of antithrombotic therapy, which implies that the devices
were used after some form of vascular intervention.
Antegrade access is more commonly used in patients with
diabetes, where below-the-knee pathology can be more
easily reached than through an over-the-bifurcation
procedure.
Deployment success was [97%. There is a signiﬁcant
difference in deployment success, with more failures in the
antegrade access group: 8.8% in the antegrade and 1.8% in
the retrograde group. Other parameters such as obesity,
sheath size, and local calciﬁcations did not seem to be
predictors for deployment failure. The latter is in contra-
diction to the instructions for use by the manufacturer of
the device. Access site complications were equal in both
antegrade and retrograde access. Minor postdeployment
bleeding was seen in 6.4% and was easily handled. This
was probably due to the mismatch between anchor and
plug, which can be seen after a puncture has been too steep.
There were 1.2% serious complications before dis-
charge, with no difference between antegrade or retrograde
access. There is one small prospective randomized trial that
compares manual compression and Angio-Seal in day-care
patients with peripheral interventional procedures [7]. In
this study, no signiﬁcant differences in complications were
found between manual compression and Angio-Seal. There
were no serious complications in either group, but there
was a 12% failure rate in deployment of the closure device.
However, there was a signiﬁcant difference in time to
hemostasis to the advantage of a closure device. The 1.2%
puncture site complications are low. One of the main
promotional reasons for the use of a closure device after an
arterial intervention in interventional radiology is early
ambulation with early discharge. However, even though
the closure device seems to be safe and effective, less than
50% of all patients were discharged within 24 h. This is
probably more a reﬂection of local reimbursement policy
than of concerns about the closure device, because the
other 50% was discharged at between 9 and 24 h. After
discharge, a 1.3% incidence of serious complications can
still be expected at the access site, and patients should be
informed of this possibility.
In general, the conclusion of this registry of closure
devices with an anchor and a plug is that the use of this
device in interventional radiology procedures is safe, with a
low incidence of serious access site complications. There
seems to be no difference in complications between ante-
grade and retrograde access and other parameters. These
results are also supported by some small and large single-
center publications [1–4, 8, 9]. There was early ambulation,
but shortening of anticipated discharge could not be pro-
ven, most likely due to external and local circumstances.
Although not part of this registry, as a result of the design
as an acute registration, patient comfort should also be an
important issue in the decision to use a closure device after
an interventional radiology procedure.
Conﬂict of interest The authors declare that they have no conﬂict
of interest.
Open Access This article is distributed under the terms of the
Creative Commons Attribution Noncommercial License which per-
mits any noncommercial use, distribution, and reproduction in any
medium, provided the original author(s) and source are credited.
References
1. Kirchhof C, Schickel S, Schmidt-Lucke C, Schmidt-Lucke JA
(2002) Local vascular complications after use of the hemostatic
puncture closure device Angio-Seal. Vasa 31:101–106
2. Kapoor B, Panu A, Berscheid B (2007) Angio-seal in antegrade
endovascular interventions: technical success and complications in
a 55-patient series. Endovasc Ther 14:382–386
52 J. A. Reekers et al.: CIRSE Vascular Closure Device Registry
1233. Kadner A, Schmidli J, Schwegler I et al (2008) Complications
associated with the arterial puncture closure device—Angio-Seal.
Vasc Endovasc Surg 42:225–227
4. Looby S, Keeling AN, McErlean A et al (2008) Efﬁcacy and safety
of the angioseal vascular closure device post antegrade puncture.
Cardiovasc Intervent Radiol 31:558–562
5. Eidt JF, Habibipour S, Saucedo JF et al (1999) Surgical
complications from hemostatic puncture closure devices. Am J
Surg 178:511–516
6. van der Steeg HJ, Berger P, Krasznai AG et al (2009) Acute
arterial occlusion after deployment of the Angio-Seal closure
device: is it as uncommon as we think? Eur J Vasc Endovasc Surg
38:715–717
7. Upponi SS, Ganeshan AG, Warakaulle DR et al (2007) Angioseal
versus manual compression for haemostasis following peripheral
vascular diagnostic and interventional procedures—a randomized
controlled trial. Eur J Radiol 61:332–334
8. Katzenschlager R, Tischler R, Kalchhauser G et al (2009) Angio-
Seal use in patients with peripheral arterial disease (ASPIRE).
Angiology 60:536–538
9. Mukhopadhyay K, Puckett MA, Roobottom CA (2005) Efﬁcacy
and complications of Angioseal in antegrade puncture. Eur J
Radiol 56:409–412
J. A. Reekers et al.: CIRSE Vascular Closure Device Registry 53
123